Skip to content

Comparing amitriptyline and gabapentin in migraine prevention

Comparison of efficacy and safety of amitriptyline with gabapentin in migraine prophylaxis: randomized double blinded double dummy trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/01/007743
Enrollment
164
Registered
2017-01-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Migraine patients with headache frequency more than 4 per month

Interventions

Intervention1: Gabapentin and Amitriptyline: Amitriptyline will be prescribed in a dose of 25 mg daily for 4 weeks which will be increased to 50 mg and maximum up to 75mg if needed depending on the re

Sponsors

JIPMER Intramural fund
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Migraine patients with headache frequency >4/month (diagnosed based on International Headache Society Criteria 3). 2. Migraine patients between 18 and 60 years of age, either gender.

Exclusion criteria

Exclusion criteria: A. Patients who have received any prophylactic medication for migraine during last 1 month. B. Patients with history of drug allergy. C. Uncontrolled hypertension, coronary artery disease. D. Pregnancy, menstrual irregularity. E. Liver or kidney dysfunction. F. Systemic or psychiatric disease. G. Malignancy. H. Those unwilling to participate in study

Design outcomes

Primary

MeasureTime frame
1. To assess and compare the prophylactic effect of gabapentin and amitriptyline on frequency and intensity of headache among migraine patients. 2. To compare the efficacy of amitriptyline and gabapentin on reducing the severity of headache using VAS score. Timepoint: 1.Patient will be initially assessed on Day 0 for headache frequency and severity and then will be assessed on Day 30,60,90 for assessing the change in headache frequency following starting amitriptyline and gabapentin. 2.Pt will also be assessed on Day 30,60,90 for change in headache severity which will be assessed by change in Visual analogue scale (VAS) score

Secondary

MeasureTime frame
1. To evaluate the effect of drug response on vascular biomarkers (Adiponectin & Leptin) in migraine prophylaxis. 2. To compare improvement in functional disability score following treatment between amitriptyline and gabapentin. 3. To compare the reduction in the number of rescue medications used between amitriptyline and gabapentin. 4. To compare adverse drug reactions between amitriptyline and gabapentin Timepoint: 1. Serum adiponectin and leptin levels will be evaluated at baseline and at end of 3 months. 2. Assessment of functional disability, reduction in use of number of rescue medication, adverse effects will be assessed on monthly basis till 3 months

Countries

India

Contacts

Public ContactDr S Sandhiya

JIPMER

vaibhavwadwekar@yahoo.co.in7598566985

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026